UNSPSC 51122602: Cholestyramine/sorbitol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV350. This VA Drug Class (CV350) classifies this compound as belonging to the group ANTILIPEMIC AGENTS.

UNSPSC 51122602 Cholestyramine/sorbitol is a Commodity code covering specialty and generic pharmaceuticals supplied to state and local emergency services, public health agencies, and cooperative purchasing alliances. State and local governments procure under this code primarily for emergency medical services, institutional pharmacy programs, and multi-state pharmaceutical distribution networks. The kinds of issuing bodies include city fire rescue departments, state health and human services commissions, and multi-state cooperative purchasing organizations. Recent solicitations show demand for both acute-care medications (emergency life support injectables) and broader generic pharmaceutical catalogs distributed through established wholesaler networks, with suppliers expected to maintain FDA compliance, cGMP certification, and Drug Supply Chain Security Act (DSCSA) adherence.

Activity appears concentrated in the South and Upper Midwest. The City of Tampa's Hillsborough County Fire Rescue issued IFB 26P00188 on April 24, 2026 (due April 8, 2026) for Advanced Life Support Medications including Labetalol, Epinephrine, Adenosine, and Diltiazem, with an estimated contract value of $40,000 and a one-year term with renewal options; the solicitation carried a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 on January 20, 2026 (due March 26, 2026) for Generic Multi Source Pharmaceuticals and OTC Products, covering participating state and local facilities in Minnesota and Oregon, with a two-year contract term and pricing weighted 75 percent on competitiveness. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, though this remains an exploratory stage without committed contract value or timeline. Vendors must expect insurance requirements including $5 million general liability and supply products with minimum six-month to nine-month shelf life from acceptance.